Summit Trail Advisors’s Sage Therapeutics SAGE Stock Holding History

Summit Trail Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-18	Closed	-$3K	–	1416
2017 Q4	$3K	Buy	+18	New	+$1.75K	﹤0.01%	1564

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Summit Trail Advisors's SAGE Position: Q1 2018 in Review

Summit Trail Advisors sold out of Sage Therapeutics (SAGE) in Q1 2018, closing a stake of 18 shares — an estimated $3K sold.

Summit Trail Advisors first reported a position in SAGE in Q4 2017 and held it in 1 quarter. The position peaked at $3K in Q4 2017. 250 funds tracked by Wall St. Rank hold SAGE as of Q1 2018.

Summit Trail Advisors reported no remaining Sage Therapeutics position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 18 Sage Therapeutics shares in Q1 2018, an estimated $3K.
Summit Trail Advisors first reported a position in Sage Therapeutics in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's Sage Therapeutics position peaked at $3K in Q4 2017.
250 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.